Dubai Science Park becomes regional hub for PTC Therapeutics’ rare disease treatments

UAE—PTC Therapeutics, a global leader in biopharmaceuticals for rare diseases, has officially opened its Middle East and North Africa (MENA) office at Dubai Science Park.

This new regional hub aims to improve access to innovative and transformative medicines for patients suffering from rare diseases across the MENA region.

PTC specializes in developing and commercializing breakthrough therapies for rare diseases worldwide.

With the launch of this facility, the company plans to strengthen its presence and operations in the region, delivering its expanding portfolio of treatments to improve health outcomes for rare disease patients.

It is estimated that about 350 million people globally are affected by rare diseases, with approximately 2.8 million patients in the Middle East alone.

Zeina Sfeir, Head of MENA at PTC Therapeutics, expressed excitement about establishing a physical presence in the region.

 She highlighted the company’s commitment to serving more patients across a diverse range of therapeutic areas with unwavering dedication.

This move reflects PTC’s goal to bring cutting-edge therapies closer to those in need within the MENA region.

Marwan Abdulaziz Janahi, Senior Vice President of Dubai Science Park, part of TECOM Group PJSC, welcomed PTC Therapeutics to the park’s innovative ecosystem.

He described Dubai Science Park as a collaborative platform that unites researchers, clinicians, and biopharmaceutical experts.

Janahi emphasized that partners like PTC play a crucial role in transforming scientific advances into effective treatments that enhance health outcomes.

He also noted that this collaboration supports key initiatives such as the Dubai Research and Development Programme, the Dubai Economic Agenda ‘D33’, and the UAE’s long-term vision, We the UAE 2031.

For nearly a decade, PTC Therapeutics has built strong partnerships with regional stakeholders.

The company has contributed significantly to improving patient outcomes in the MENA region by providing transformative treatments, including therapies for Duchenne Muscular Dystrophy (DMD) and a gene therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

These efforts have helped many patients’ access life-changing medicines that were previously difficult to obtain.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.